激动剂-话题@MedSci

#激动剂#

173篇内容 | 3680人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1627806, encodeId=18e4162e8062c, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病, objectType=article, longId=187289, objectId=33a518e289cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33a518e289cb, replyNumber=0, likeNumber=62, createdTime=2020-02-04, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33a518e289cb, moduleTitle=欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33a518e289cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627805, encodeId=ecda162e8056a, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=J Hepatology：法尼醇X受体激动剂对非酒精性脂肪性肝炎患者脂蛋白谱的影响, objectType=article, longId=186945, objectId=51681869456c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51681869456c, replyNumber=0, likeNumber=75, createdTime=2020-01-31, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51681869456c, moduleTitle=J Hepatology：法尼醇X受体激动剂对非酒精性脂肪性肝炎患者脂蛋白谱的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51681869456c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627804, encodeId=3b93162e80423, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Eur Respir J：哮喘患者过度使用短效β2受体激动剂会增加病情加重和死亡的风险, objectType=article, longId=186568, objectId=e6dd1865688c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6dd1865688c, replyNumber=0, likeNumber=66, createdTime=2020-01-21, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6dd1865688c, moduleTitle=Eur Respir J：哮喘患者过度使用短效β2受体激动剂会增加病情加重和死亡的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6dd1865688c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627803, encodeId=3439162e80330, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401, objectType=article, longId=185937, objectId=58ff18593e64, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58ff18593e64, replyNumber=0, likeNumber=28, createdTime=2020-01-10, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58ff18593e64, moduleTitle=Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58ff18593e64)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627802, encodeId=3064162e80214, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Chest：吸入性糖皮质激素和长效β2激动剂联合治疗慢性阻塞性肺疾病的安全性和疗效, objectType=article, longId=185417, objectId=2bb918541e74, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bb918541e74, replyNumber=0, likeNumber=54, createdTime=2019-12-31, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bb918541e74, moduleTitle=Chest：吸入性糖皮质激素和长效β2激动剂联合治疗慢性阻塞性肺疾病的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bb918541e74)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627801, encodeId=0bd6162e8017f, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Stroke：胰高血糖素样肽1受体激动剂与卒中预防, objectType=article, longId=184504, objectId=319c184504d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=319c184504d6, replyNumber=0, likeNumber=60, createdTime=2019-12-11, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=319c184504d6, moduleTitle=Stroke：胰高血糖素样肽1受体激动剂与卒中预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=319c184504d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627800, encodeId=3d53162e80039, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Minoryx公司的PPRP激动剂来瑞格列酮治疗Friedreich共济失调，获得FDA孤儿药称号, objectType=article, longId=181655, objectId=22581816559a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22581816559a, replyNumber=0, likeNumber=80, createdTime=2019-10-22, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22581816559a, moduleTitle=Minoryx公司的PPRP激动剂来瑞格列酮治疗Friedreich共济失调，获得FDA孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22581816559a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627799, encodeId=0086162e799ce, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JCEM：多巴胺受体激动剂治疗的高泌乳素血症患者冲动控制障碍, objectType=article, longId=180531, objectId=7eb41805316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7eb41805316b, replyNumber=0, likeNumber=62, createdTime=2019-10-07, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7eb41805316b, moduleTitle=JCEM：多巴胺受体激动剂治疗的高泌乳素血症患者冲动控制障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7eb41805316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627798, encodeId=3ad7162e7989e, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Enanta宣布其FXR激动剂EDP-305治疗非酒精性脂肪性肝炎的临床研究积极成果, objectType=article, longId=180093, objectId=cf0518009397, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0518009397, replyNumber=0, likeNumber=27, createdTime=2019-09-28, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0518009397, moduleTitle=Enanta宣布其FXR激动剂EDP-305治疗非酒精性脂肪性肝炎的临床研究积极成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0518009397)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627797, encodeId=027e162e79767, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=G蛋白偶联受体激动剂OK-113：具有强效抗炎作用, objectType=article, longId=178363, objectId=b2471e836310, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2471e836310, replyNumber=0, likeNumber=71, createdTime=2019-08-31, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2471e836310, moduleTitle=G蛋白偶联受体激动剂OK-113：具有强效抗炎作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2471e836310)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627796, encodeId=9f9c162e79660, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Lancet Diabetes Endo：GLP-1激动剂对心血管事件、死亡率及肾脏事件的影响, objectType=article, longId=177735, objectId=9d381e773577, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d381e773577, replyNumber=0, likeNumber=78, createdTime=2019-08-17, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d381e773577, moduleTitle=Lancet Diabetes Endo：GLP-1激动剂对心血管事件、死亡率及肾脏事件的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d381e773577)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627795, encodeId=c693162e79579, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=2019 南亚工作组共识建议：应用胰高血糖素样肽-1受体激动剂 (GLP-1 RAs)治疗2型糖尿病, objectType=article, longId=176930, objectId=78571e6930a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78571e6930a3, replyNumber=0, likeNumber=44, createdTime=2019-08-06, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78571e6930a3, moduleTitle=2019 南亚工作组共识建议：应用胰高血糖素样肽-1受体激动剂 (GLP-1 RAs)治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78571e6930a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627794, encodeId=6be6162e79465, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=GUT：术前给予5-HT4受体激动剂-普卢卡必利可通过胆碱能肠神经元减少肠道炎症并缩短术后肠梗阻时间, objectType=article, longId=176761, objectId=73ab1e67611c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73ab1e67611c, replyNumber=0, likeNumber=68, createdTime=2019-08-04, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73ab1e67611c, moduleTitle=GUT：术前给予5-HT4受体激动剂-普卢卡必利可通过胆碱能肠神经元减少肠道炎症并缩短术后肠梗阻时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73ab1e67611c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627793, encodeId=5790162e79364, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Boehringer Ingelheim与韩国Yuhan签订8.7亿美元合同，合作开发非酒精性脂肪性肝炎的双重激动剂, objectType=article, longId=174741, objectId=97ed1e4741da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97ed1e4741da, replyNumber=0, likeNumber=107, createdTime=2019-07-05, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97ed1e4741da, moduleTitle=Boehringer Ingelheim与韩国Yuhan签订8.7亿美元合同，合作开发非酒精性脂肪性肝炎的双重激动剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97ed1e4741da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627792, encodeId=9431162e79245, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, objectType=article, longId=167983, objectId=85e516e98361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85e516e98361, replyNumber=0, likeNumber=91, createdTime=2019-06-12, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85e516e98361, moduleTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85e516e98361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627791, encodeId=1ff4162e7917d, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, objectType=article, longId=167970, objectId=f88316e97041, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88316e97041, replyNumber=0, likeNumber=64, createdTime=2019-06-11, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88316e97041, moduleTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f88316e97041)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627790, encodeId=244f162e79015, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, objectType=article, longId=167543, objectId=1bb016e5435e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb016e5435e, replyNumber=0, likeNumber=44, createdTime=2019-06-04, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb016e5435e, moduleTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bb016e5435e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627789, encodeId=ed68162e7893d, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Neurology：β2AR激动剂/拮抗剂与帕金森病的相关性, objectType=article, longId=167138, objectId=f45116e138f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f45116e138f4, replyNumber=0, likeNumber=66, createdTime=2019-05-31, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f45116e138f4, moduleTitle=Neurology：β2AR激动剂/拮抗剂与帕金森病的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f45116e138f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627788, encodeId=2208162e78868, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=2019年欧洲肝脏研究协会大会：PPARδ激动剂Seladelpar治疗原发性胆汁性胆管炎患者的II期阳性数据, objectType=article, longId=164229, objectId=06b01642297b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06b01642297b, replyNumber=0, likeNumber=57, createdTime=2019-04-15, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06b01642297b, moduleTitle=2019年欧洲肝脏研究协会大会：PPARδ激动剂Seladelpar治疗原发性胆汁性胆管炎患者的II期阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06b01642297b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627787, encodeId=bfa6162e7873c, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Lancet：辅助个性化心理社会干预治疗阿片受体激动剂治疗耐药维持的疗效和成本效益, objectType=article, longId=163536, objectId=6a49163536dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a49163536dc, replyNumber=0, likeNumber=74, createdTime=2019-04-05, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a49163536dc, moduleTitle=Lancet：辅助个性化心理社会干预治疗阿片受体激动剂治疗耐药维持的疗效和成本效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a49163536dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激动剂

2020-05-29

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病

2020-02-04

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

J Hepatology：法尼醇X受体激动剂对非酒精性脂肪性肝炎患者脂蛋白谱的影响

2020-01-31

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Eur Respir J：哮喘患者过度使用短效β2受体激动剂会增加病情加重和死亡的风险

2020-01-21

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401

2020-01-10

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Chest：吸入性糖皮质激素和长效β2激动剂联合治疗慢性阻塞性肺疾病的安全性和疗效

2019-12-31

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Stroke：胰高血糖素样肽1受体激动剂与卒中预防

2019-12-11

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Minoryx公司的PPRP激动剂来瑞格列酮治疗Friedreich共济失调，获得FDA孤儿药称号

2019-10-22

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JCEM：多巴胺受体激动剂治疗的高泌乳素血症患者冲动控制障碍

2019-10-07

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Enanta宣布其FXR激动剂EDP-305治疗非酒精性脂肪性肝炎的临床研究积极成果

2019-09-28

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

G蛋白偶联受体激动剂OK-113：具有强效抗炎作用

2019-08-31

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Lancet Diabetes Endo：GLP-1激动剂对心血管事件、死亡率及肾脏事件的影响

2019-08-17

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

2019 南亚工作组共识建议：应用胰高血糖素样肽-1受体激动剂 (GLP-1 RAs)治疗2型糖尿病

2019-08-06

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

GUT：术前给予5-HT4受体激动剂-普卢卡必利可通过胆碱能肠神经元减少肠道炎症并缩短术后肠梗阻时间

2019-08-04

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Boehringer Ingelheim与韩国Yuhan签订8.7亿美元合同，合作开发非酒精性脂肪性肝炎的双重激动剂

2019-07-05

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平

2019-06-12

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力

2019-06-11

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据

2019-06-04

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Neurology：β2AR激动剂/拮抗剂与帕金森病的相关性

2019-05-31

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

2019年欧洲肝脏研究协会大会：PPARδ激动剂Seladelpar治疗原发性胆汁性胆管炎患者的II期阳性数据

2019-04-15

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Lancet：辅助个性化心理社会干预治疗阿片受体激动剂治疗耐药维持的疗效和成本效益

2019-04-05

科室
- - 订阅+
  - 更多科室
工具
服务